Results 51 to 60 of about 58,432 (298)
International Archives of Otorhinolaryngology, 2016 Introduction High mobility group box 1 is a versatile protein involved in gene transcription, extracellular signaling, and response to inflammation. Extracellularly, high mobility group box 1 binds to several receptors, notably the receptor for advanced ...
Austin Nguyen +4 more
doaj +1 more source
Dietary Advanced Glycation End Products and Aging [PDF]
Nutrients, 2010 Advanced glycation end products (AGEs) are a heterogeneous, complex group of compounds that are formed when reducing sugar reacts in a non-enzymatic way with amino acids in proteins and other macromolecules. This occurs both exogenously (in food) and endogenously (in humans) with greater concentrations found in older adults.
Luevano-Contreras, Claudia +1 more
openaire +2 more sources
Advanced glycation end products
, 2022 Advanced glycation end products (AGEs) are a heterogeneous group of compounds formed by non-enzymatic interactions between the carbonyl groups of reducing sugars and free amino groups of proteins, lipids, or nucleic acids.
Dat, Pham Thai
core
Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development
, 2022 Type 1 diabetes (T1D) is an autoimmune disease in which the β-cells of the pancreas are attacked by the host’s immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination
Rani O. Whiddett +14 more
core +1 more source
Tumor Biology, 2017 Receptor for advanced glycation end products and glyoxalase I metabolizing advanced glycation end product precursors may play important role in the pathogenesis and progression of cancer.
Petra Tesarova +3 more
doaj +1 more source
Evaluation of the AGE/sRAGE Axis in Patients with Multiple Myeloma
Antioxidants, 2019 Glycative stress influences tumor progression. The aim of the present study was to evaluate the advanced glycation end products/soluble receptor of advanced glycation end products (AGE/sRAGE) axis in patients with multiple myeloma (MM).
Alessandro Allegra +10 more
doaj +1 more source
Advanced Glycation End-products and Atherosclerosis
Annals of Medicine, 1996 The late rearrangements of the covalent nonenzymatic modification of proteins by glucose, called advanced glycation end-products (AGEs), have been shown to accumulate in diabetic and ageing tissues. AGEs elicit a wide range of cell-mediated responses leading to vascular dysfunction, matrix expansion and athero- and glomerulosclerosis.
openaire +2 more sources
Advanced Glycation End Products in Clinical Nephrology
Kidney and Blood Pressure Research, 2004 As a result of oxidative and carbonyl stress, advanced glycation end products (AGEs) are involved in the pathogenesis of severe and frequent diseases and their fatal vascular/cardiovascular complications, i.e. diabetes mellitus and its complications (nephropathy, angiopathy, neuropathy and retinopathy, renal failure and uremic and dialysis-associated ...
M, Kalousová +4 more
openaire +2 more sources
Toxicity of advanced glycation end products (Review)
Biomedical Reports, 2021 Advanced glycation end-products (AGEs) are proteins or lipids glycated nonenzymatically by glucose, or other reducing sugars and their derivatives, such as glyceraldehyde, glycolaldehyde, methyloglyoxal and acetaldehyde. There are three different means of AGE formation: i) Maillard reactions, the polyol pathway and lipid peroxidation.
openaire +4 more sources
Advanced glycation end products and diabetic retinopathy [PDF]
Journal of Ocular Biology, Diseases, and Informatics, 2012 Studies have established hyperglycemia as the most important factor in the progress of vascular complications. Formation of advanced glycation end products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that hyperglycemia contributes to the pathogenesis of diabetic complications including retinopathy.
Yashodhara, Sharma +4 more
openaire +2 more sources